Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 6, pp. 755-768
Open Access | Times Cited: 47

Showing 1-25 of 47 citing articles:

Cold and hot tumors: from molecular mechanisms to targeted therapy
Bo Wu, Bo Zhang, Bowen Li, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 34
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
Ishmael Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. e23-e43
Closed Access | Times Cited: 25
CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non–Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy
Joel W. Neal, Nick Pavlakis, Sang‐We Kim, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 20, pp. 2393-2403
Open Access | Times Cited: 15
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
Yibei Wang, Mohammed Safi, Fred R. Hirsch, et al.
Nature Reviews Clinical Oncology (2025) Vol. 22, Iss. 3, pp. 200-214
Closed Access | Times Cited: 1
Non–Small Cell Lung Cancer Metastatic Without Oncogenic Alterations
Nikolaj Frost, Martin Reck
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6
Immune checkpoint inhibitors plus platinum-based chemotherapy compared to platinum-based chemotherapy with or without bevacizumab for first-line treatment of older people with advanced non-small cell lung cancer
Émeline Orillard, Arjab Adhikari, Reem Malouf, et al.
Cochrane library (2024) Vol. 2024, Iss. 8
Closed Access | Times Cited: 5
A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
Jie Fu, Yi‐Dan Yan, Xu Wan, et al.
Frontiers in Pharmacology (2025) Vol. 15
Open Access
Comparative efficacy and safety of first‑line PD‑1/PD‑L1 inhibitors in immunotherapy for non‑small cell lung cancer: A network meta‑analysis
Liyan Liu, Yilong Yan, Yuqiao Wang, et al.
Oncology Letters (2025) Vol. 29, Iss. 3
Open Access
Immune checkpoint inhibitors plus taxane-based chemotherapy for patients with advanced/metastatic NSCLC: a systematic review and meta-analysis across different PD-L1 expression levels
Aws Khalid Abushanab, Mus’ab Theeb Mustafa, Mahmoud Taysir Mousa, et al.
Expert Review of Anticancer Therapy (2025)
Closed Access
Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non–small cell lung cancer
Xiangzhong Xue, Surachat Ngorsuraches, Brandon Johnson, et al.
Journal of Managed Care & Specialty Pharmacy (2025) Vol. 31, Iss. 2, pp. 137-146
Closed Access
Camrelizumab-based therapies for the treatment of advanced lung cancer: a prospective, open-label, multicenter, observational, real-world study
Dong Zhao, Minghong Bi, Xiaofei Cheng, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Traitement standard de première ligne des carcinomes bronchiques non à petites cellules métastatiques sans addiction oncogénique
Romane Gille, M. Pérol
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S64-3S74
Closed Access
Are all programmed cell death protein 1 inhibitors the same?
Jochen H. Lorch, Stacey Stein, Martin J. Edelman
Frontiers in Oncology (2025) Vol. 15
Open Access
Update in Immunotherapy for Advanced Non-Small Cell Lung Cancer: Optimizing Treatment Sequencing and Identifying the Best Choices
Kátia Roque, Rossana Ruiz, Luís Más, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4547-4547
Open Access | Times Cited: 9
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions
Angela Rina, Debora Maffeo, Francesca Minnai, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2882-2882
Open Access | Times Cited: 3
Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy
Xiaobing Li, Yi Peng, De Pei Wu, et al.
Journal of Chemotherapy (2024), pp. 1-9
Closed Access | Times Cited: 3
Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab–Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis
Solange Peters, Luís Paz-Ares, Martin Reck, et al.
Journal of Thoracic Oncology (2024) Vol. 20, Iss. 1, pp. 94-108
Open Access | Times Cited: 3
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT)
Cesare Gridelli, Solange Peters, Tony Mok, et al.
Lung Cancer (2023) Vol. 187, pp. 107441-107441
Open Access | Times Cited: 8
Biomarkers for Immunotherapy in Driver-Gene-Negative Advanced NSCLC
Yiyi Huang, Yi-Fung Chau, Hua Bai, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 19, pp. 14521-14521
Open Access | Times Cited: 7
Adverse events associated with immune checkpoint inhibitors in non-small cell lung cancer: a safety analysis of clinical trials and FDA pharmacovigilance system
Xueyan Liang, Hewei Xiao, Huijuan Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
The role of immunotherapy in early-stage and metastatic NSCLC
Attila Lieber, Attila Makai, Zsuzsanna Orosz, et al.
Pathology & Oncology Research (2024) Vol. 30
Open Access | Times Cited: 2
Spotlight on Cemiplimab-rwlc in the Treatment of Non-Small Cell Lung Cancer (NSCLC): Focus on Patient Selection and Considerations
Jeffrey Ahn, Misako Nagasaka
Cancer Management and Research (2023) Vol. Volume 15, pp. 627-634
Open Access | Times Cited: 5
Novel immunotherapeutic approaches in lung cancer: driving beyond programmed death-1/programmed death ligand-1 and cytotoxic T-lymphocyte-associated Protein-4
Blerina Resuli, Diego Kauffmann-Guerrero
Current Opinion in Oncology (2024)
Closed Access | Times Cited: 1
Camrelizumab plus carboplatin and pemetrexed as first-line therapy for advanced non-squamous non-small-cell lung cancer: 5-year outcomes of the CameL randomized phase 3 study
Caicun Zhou, Gongyan Chen, Yunchao Huang, et al.
Journal for ImmunoTherapy of Cancer (2024) Vol. 12, Iss. 11, pp. e009240-e009240
Open Access | Times Cited: 1
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC?
Danielle Brazel, Sai‐Hong Ignatius Ou
Lung Cancer Targets and Therapy (2023) Vol. Volume 14, pp. 63-69
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top